|
| Press Releases |
|
 |
|
| Wednesday, April 17, 2024 |
|
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物、海外製品名：「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
| Friday, August 4, 2023 |
|
|
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の構成銘柄に22年連続で選定 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来22年連続で選定されたことをお知らせします。 more info >> |
|
|
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002. more info >> |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
| Thursday, March 21, 2024 |
|
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
香港鐘表展及國際名表薈萃圓滿結束
Sept 8, 2024 15:25 HKT/SGT
|
|
|
Annual fashion spotlight CENTRESTAGE draws more than 8,500 buyers
Sept 7, 2024 20:19 HKT/SGT
|
|
|
TANAKA Precious Metals Announces Executive Appointments
Sept 7, 2024 3:00 JST
|
|
|
Amazfit Launches T-Rex 3, the Ultimate Adventure Companion
Sept 6, 2024 20:00 HKT/SGT
|
|
|
周大福人寿2024年上半年 首年年化保费收入按年上升33% 持续强劲增长势头
Sept 6, 2024 17:01 HKT/SGT
|
|
|
周大福人壽2024年上半年 首年年化保費收入按年上升33% 持續強勁增長勢頭
Sept 6, 2024 16:42 HKT/SGT
|
|
|
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sept 6, 2024 16:34 JST
|
|
|
GTJAI Receives Multiple Awards in Bond Connect 2024 Awards
Sept 6, 2024 15:32 HKT/SGT
|
|
|
國泰君安國際榮獲2024年度「債券通」多項殊榮 彰顯互聯互通業務實力
Sept 6, 2024 15:25 HKT/SGT
|
|
|
国泰君安国际荣获2024年度“债券通”多项殊荣 彰显互联互通业务实力
Sept 6, 2024 15:16 HKT/SGT
|
|
|
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sept 6, 2024 15:10 JST
|
|
|
Reopening of CENTRESTAGE, Hong Kong Watch & Clock Fair and Salon de TIME
Sept 6, 2024 11:10 HKT/SGT
|
|
|
transport logistic and air cargo Southeast Asia: Fueling Regional Economic Growth
Sept 6, 2024 10:09 HKT/SGT
|
|
|
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sept 6, 2024 9:26 JST
|
|
|
How Much Do Vegan Diets Improve the Health of Dogs?
Sept 6, 2024 07:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
